GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (FRA:YDO1) » Definitions » Cyclically Adjusted PB Ratio

Madrigal Pharmaceuticals (FRA:YDO1) Cyclically Adjusted PB Ratio : 11.07 (As of Apr. 28, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Madrigal Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-04-28), Madrigal Pharmaceuticals's current share price is €179.30. Madrigal Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was €16.19. Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 11.07.

The historical rank and industry rank for Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:YDO1' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 15.74
Current: 10.75

During the past years, Madrigal Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 15.74. The lowest was 0.00. And the median was 0.00.

FRA:YDO1's Cyclically Adjusted PB Ratio is ranked worse than
90.8% of 641 companies
in the Biotechnology industry
Industry Median: 1.72 vs FRA:YDO1: 10.75

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Madrigal Pharmaceuticals's adjusted book value per share data for the three months ended in Dec. 2023 was €18.701. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €16.19 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Madrigal Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Madrigal Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.55 5.84 4.27 15.36 12.87

Madrigal Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.36 13.10 12.66 8.02 12.87

Competitive Comparison of Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Madrigal Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=179.30/16.19
=11.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Madrigal Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Madrigal Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=18.701/129.4194*129.4194
=18.701

Current CPI (Dec. 2023) = 129.4194.

Madrigal Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 11.043 99.695 14.336
201406 18.816 100.560 24.216
201409 20.883 100.428 26.912
201412 16.944 99.070 22.135
201503 13.675 99.621 17.765
201506 16.046 100.684 20.626
201509 13.664 100.392 17.615
201512 -11.406 99.792 -14.792
201603 10.111 100.470 13.024
201606 9.398 101.688 11.961
201609 2.895 101.861 3.678
201612 2.888 101.863 3.669
201703 2.647 102.862 3.330
201706 4.390 103.349 5.497
201709 3.646 104.136 4.531
201712 10.825 104.011 13.469
201803 10.083 105.290 12.394
201806 27.080 106.317 32.964
201809 26.885 106.507 32.669
201812 27.209 105.998 33.221
201903 26.894 107.251 32.453
201906 26.217 108.070 31.396
201909 25.914 108.329 30.959
201912 24.299 108.420 29.005
202003 22.610 108.902 26.870
202006 19.725 108.767 23.470
202009 15.903 109.815 18.742
202012 12.719 109.897 14.978
202103 13.625 111.754 15.779
202106 13.533 114.631 15.279
202109 11.841 115.734 13.241
202112 10.147 117.630 11.164
202203 7.737 121.301 8.255
202206 4.620 125.017 4.783
202209 0.630 125.227 0.651
202212 10.293 125.222 10.638
202303 7.670 127.348 7.795
202306 5.176 128.729 5.204
202309 1.127 129.860 1.123
202312 18.701 129.419 18.701

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Madrigal Pharmaceuticals  (FRA:YDO1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Madrigal Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Madrigal Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Madrigal Pharmaceuticals (FRA:YDO1) Business Description

Traded in Other Exchanges
Address
200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Madrigal Pharmaceuticals (FRA:YDO1) Headlines

No Headlines